Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Virica Biotech, Oxford Biomedica Enter R&D Partnership | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Virica Biotech, Oxford Biomedica Enter R&D Partnership

To improve the manufacturing of lentiviral vector gene therapies using viral sensitizers.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Virica Biotech, a developer of solutions for scaling of viral medicines, is collaborating with Oxford Biomedica to improve the yield and production efficiency of Oxford’s next generation lentiviral vector gene therapies using Virica’s Viral Sensitizers (VSEs).

“There is growing demand from major industry players to use leading lentivirus technologies, like Oxford Biomedica’s LentiVector platform, to develop cell and gene therapies,” said Ella Korets-Smith, chief business officer, Virica Biotech. “We envision our VSEs as an ideal solution in their quest to pursue new ways to increase commercial yields in order to support the use of life-saving cell and gene therapies globally.”

Oxford Biomedica is a pioneer of cell and gene therapies. Its LentiVector platform enables the successful development of breakthrough gene and cell-based medicines, and through collaborations with pharmaceutical partners, has delivered the first FDA and EMA approved CAR-T cell therapy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics